Literature DB >> 26209900

Management of Hypereosinophilic Syndromes.

Florence Roufosse1.   

Abstract

The symptomatic hypereosinophilic patient must be approached in a stepwise manner, with thorough assessment to determine whether the hypereosinophilia itself is contributing to damage and disease manifestations (thereby defining a hypereosinophilic syndrome), and to identify an eventual cause of hypereosinophilia, followed by initiation of treatment directed against the underlying condition or deleterious hypereosinophilic state. Situations encountered in the clinic are extremely heterogeneous because of the numerous potential causes of hypereosinophilia and the variable spectrum of eosinophil-mediated organ damage. A practical approach to many of these situations is presented in this review.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Corticosteroid; FIP1L1-PDGFRA–associated myeloid neoplasm; Hydroxyurea; Idiopathic hypereosinophilic syndrome; Imatinib mesylate; Interferon-α; Lymphocytic variant hypereosinophilic syndrome; Targeted therapy

Mesh:

Substances:

Year:  2015        PMID: 26209900     DOI: 10.1016/j.iac.2015.05.006

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN: 0889-8561            Impact factor:   3.479


  9 in total

Review 1.  Diagnosis and Novel Approaches to the Treatment of Hypereosinophilic Syndromes.

Authors:  Melanie C Dispenza; Bruce S Bochner
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

2.  FIP1L1-PDGFRA fusion-negative hypereosinophilic syndrome with uncommon cardiac involvement responding to imatinib treatment: A case report.

Authors:  Amanda Santos Dal Berto; Ricardo Hohmann Camiña; Eduardo Silva Machado; Antuani Rafael Baptistella
Journal:  Mol Clin Oncol       Date:  2018-05-21

3.  Hypereosinophilic Syndrome with Advanced-Stage Loeffler Endocarditis.

Authors:  Sanja Dzelebdzic; Nao Sasaki; Elizabeth Welch; Juan Carlos Muniz
Journal:  CASE (Phila)       Date:  2022-04-06

Review 4.  Hypereosinophilic syndrome presenting with multiple organ infiltration and deep venous thrombosis: A case report and literature review.

Authors:  Su-Jun Gao; Wei Wei; Jiang-Tao Chen; Ye-Hui Tan; Cheng-Bao Yu; Mark Robert Litzow; Qiu-Ju Liu
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

5.  Rapid Change in Mental Status in a Patient with Hypereosinophilia.

Authors:  Hanyin Wang; John K Erban
Journal:  Case Rep Hematol       Date:  2017-01-10

6.  A case report of Löffler endocarditis in idiopathic hypereosinophilic syndrome: recovery is possible.

Authors:  Rasha Mohamed Abayazeed; Mohamed Ayman Abdel-Hay; Sara Elfwal; Mahmoud Hssanein
Journal:  Eur Heart J Case Rep       Date:  2018-03-13

7.  Acute pulmonary embolism and deep vein thrombosis secondary to idiopathic hypereosinophilic syndrome.

Authors:  Dezhi Li; Li Xu; Dianjie Lin; Shujuan Jiang; Saran Feng; Ling Zhu
Journal:  Respir Med Case Rep       Date:  2018-09-10

8.  Idiopathic hypereosinophilic syndrome in hemodialysis patients: Case reports.

Authors:  Yuko Mutsuyoshi; Keiji Hirai; Junki Morino; Shohei Kaneko; Saori Minato; Katsunori Yanai; Hiroki Ishii; Momoko Matsuyama; Taisuke Kitano; Akinori Aomatsu; Haruhisa Miyazawa; Kiyonori Ito; Yuichiro Ueda; Susumu Ookawara; Yoshiyuki Morishita
Journal:  Medicine (Baltimore)       Date:  2021-03-12       Impact factor: 1.817

9.  A patient with germ-line gain-of-function PDGFRB p.N666H mutation and marked clinical response to imatinib.

Authors:  Dinel Pond; Florence A Arts; Nancy J Mendelsohn; Jean-Baptiste Demoulin; Gunter Scharer; Yoav Messinger
Journal:  Genet Med       Date:  2017-07-20       Impact factor: 8.822

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.